Publikationen 2025

49. Favorable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second line treatment in chronic phase chronic myeloid leukemia (CML-CP) patients failing or intolerant to first-line second generation tyrosine kinase inhibitor (TKI) treatment: Results of the prospective PONS trial. le Coutre P, Burchert A, Saußele S, Schwarzer T, Stintzing S, Pelzer U, Bullinger L, Elmaagacli A, Jehn C, Stegelmann F, Hochhaus A, Ernst T, Göthert JR.
Acta Haematol. 2025 May 5:1-13. doi: 10.1159/000545826. Online ahead of print. PMID: 40324350

48. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Arellano ML, Thirman MJ, DiPersio JF, Heiblig M, Stein EM, Schuh AC, Zucenka A, De Botton S, Grove CS, Mannis GN, Papayannidis C, Perl AE, Issa GC, Aldoss I, Bajel A, Dickens DS, Kühn MWM, Mantzaris I, Raffoux E, Traer E, Amitai I, Döhner H, Greco C, Kovacsovics TJ, McMahon CM, Montesinos P, Pigneux A, Shami PJ, Stone RM, Wolach O, Harpel JG, Chudnovsky Y, Yu L, Bagley RG, Smith AR, Blachly JS.
Blood. 2025 May 7:blood.2025028357. doi: 10.1182/blood.2025028357. Online ahead of print. PMID: 40332046

47. Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment, and follow-up. d'Amore F, Federico M, de Leval L, Ellin F, Hermine O, Kim WS, Lemonnier F, Vermaat JSP, Wulf G, Buske C, Dreyling M, Jerkeman M; ESMO and EHA Guidelines Committees.
Hemasphere. 2025 May 7;9(5):e70128. doi: 10.1002/hem3.70128. eCollection 2025 May. PMID: 40342876 Free PMC article. No abstract available.

46. Report of Consensus Panel 5 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors. Castillo JJ, Autore F, Berinstein NL, Branagan AR, Dimopoulos MA, Fernandez de Larrea C, Ferrero S, Kapoor P, Kastritis E, Khwaja J, Minnema MC, Qiu L, Seymour JF, Vos JMI, Patterson CJ, Buske C, Matous JV, Treon SP, Palomba ML.
Semin Hematol. 2025 Apr 8:S0037-1963(25)00014-9. doi: 10.1053/j.seminhematol.2025.04.004. Online ahead of print. PMID: 40379542

45. Report of Consensus Panel 4 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with non-IgM lymphoplasmacytic lymphoma. Tedeschi A, Auer R, Autore F, Castillo JJ, Gatt ME, Kimby E, Moreno DF, Owen RG, Qiu L, Roccaro AM, Sarosiek S, Sekiguchi N, Seymour JF, Varettoni M, Patterson CJ, Matous JV, Buske C, Treon SP, Sanz RG.
Semin Hematol. 2025 Apr 8:S0037-1963(25)00012-5. doi: 10.1053/j.seminhematol.2025.04.002. Online ahead of print. PMID: 40382197

44. Report of Consensus Panel 6 from the 12th International Workshop on Waldenström's Macroglobulinemia on Diagnosis and Management of Transformed Waldenström's Macroglobulinemia. Durot E, Abeykoon JP, Roos-Weil D, Kersten MJ, Kyriakou C, Moreno DF, Ansell SM, Auer R, Cao X, Owen RG, Yi S, Dogliotti I, Trneny M, Patterson CJ, Matous JV, Buske C, Treon SP, Advani R.
Semin Hematol. 2025 Apr 8:S0037-1963(25)00013-7. doi: 10.1053/j.seminhematol.2025.04.003. Online ahead of print. PMID: 40382198

43. Prognostic impact of clonal representation of myelodysplasia-related gene mutations in acute myeloid leukemia. Mecklenbrauck R, Borchert N, Gabdoulline R, Poll P, Funke C, Brandes M, Dallmann LK, Fiedler W, Krauter J, Trummer A, Hertenstein B, Müller M, Lübbert M, Schwalenberg M, Voss A, Di Donato N, Bergmann A, Gaidzik V, Döhner K, Döhner H, Ganser A, Heidel FH, Thol FR, Heuser M.
Leukemia. 2025 Apr 28. doi: 10.1038/s41375-025-02622-6. Online ahead of print. PMID: 40295828 No abstract available.

42. Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma. Shumilov E, Scholz JK, Seib M, Mazzeo P, Wurm-Kuczera R, Vucinic V, Holtick U, Boyadzhiev H, Melchardt T, Hölscher AS, Schultze-Florey CR, Abdelhafez A, Velazquez GF, Ossami Saidy A, Lesan V, Schnetzke U, Kerkhoff A, Bacher U, Ghandili S, Aydilek E, Gebauer N, Weber T, Wulf GG, Glass B, Thurner L, Heidel FH, Schmid C, Viardot A, Hänel M, Dietrich S, Pabst T, Ayuk FA, von Tresckow B, Chapuy B, Pott C, Müller F, Lenz G.
Blood Adv. 2025 Apr 16:bloodadvances.2024015719. doi: 10.1182/bloodadvances.2024015719. Online ahead of print. PMID: 40238938

41. International Consensus Statement on Diagnosis, Evaluation, and Research of Richter Transformation: the ERIC Recommendations. Kittai AS, Marchetti M, Al-Sawaf O, Benjamini O, Danilov AV, Davids MS, Eichhorst BF, Eyre TA, Frustaci AM, Hallek MJ, Hampel PJ, Herishanu Y, Hicks RJ, Kater AP, King RL, Martín-Subero JI, Owen C, Parry EM, Ponzoni M, Rossi D, Siddiqi T, Stilgenbauer S, Tam CS, Ten Hacken E, Thompson PA, Wierda WG, Gaidano G, Woyach JA, Ghia P.
Blood. 2025 Apr 16:blood.2024028064. doi: 10.1182/blood.2024028064. Online ahead of print. PMID: 40239121

40. The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy. Daver NG, Vyas P, Huls GA, Döhner H, Maury S, Novak J, Papayannidis C, Martinez Chamorro C, Montesinos P, Niroula R, Fenaux P, Esteve J, Wu SJ, De Voeght A, Mayer J, Valk PJM, Johnson L, Dong M, Liu K, Kuwahara SB, Caldwell K, Guru Murthy GS.
Blood. 2025 Apr 15:blood.2024027506. doi: 10.1182/blood.2024027506. Online ahead of print.PMID: 40233321

39. A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma. Frenking JH, Riedhammer C, Teipel R, Bassermann F, Besemer B, Bewarder M, Braune J, Brioli A, Brunner F, Dampmann M, Fenk R, Gezer DN, Goldman-Mazur S, Hanoun C, Högner M, Khandanpour C, Kolditz K, Kos I, Krönke J, Kull M, Landrin V, Leitner T, Merz M, von Metzler I, Michel CS, Müller-Tidow C, Theurich S, Trautmann-Grill K, Wäsch R, Zukovs R, Hänel M, Rasche L, Raab MS.
Hemasphere. 2025 Apr 17;9(4):e70114. doi: 10.1002/hem3.70114. eCollection 2025 Apr.

38. Correction: The sarcoma ring trial: a case-based analysis of inter-center agreement across 21 German-speaking sarcoma centers. Roohani S, Handtke J, Hummedah K, Albertsmeier M, Andreou D, Apostolidis L, Augustin M, Bauer S, Billner M, Bösch F, Deinzer CKW, Deventer N, Duprée A, Eckert F, Engel L, Fechner K, Fritzsche H, Gaidzik V, Ghani S, Grützmann R, Guder WK, Hamacher R, Hecker JS, Hendricks A, Hillmann A, Houben P, Hübner G, Ivanyi P, Jentsch C, Jordan M, Kappl P, Kaths M, Kessler T, Kirchberg J, Knebel C, Krempien R, Lehner B, Lenze U, Lindner LH, Lörsch AM, Maguire N, Müller S, Piso P, Potkrajcic V, Reichardt P, Richter S, Schewe S, Schiffmann LM, Scholten F, Striefler JK, Schwarzbach M, Seidensaal K, Semrau S, Szkandera J, Szuszies CJ, Timmermann B, Tuchscherer A, Wiegering A, Winkelmann MT, Kaul D, Jakob J.
J Cancer Res Clin Oncol. 2025 Apr 24;151(4):149.

37. Enhancer hijacking discovery in acute myeloid leukemia by pyjacker identifies MNX1 activation via deletion 7q. Sollier E, Riedel A, Toprak UH, Wierzbinska JA, Weichenhan D, Schmid JP, Hakobyan M, Touzart A, Jahn E, Vick B, Brown-Burke F, Kelly K, Kelekci S, Pejkovska A, Goyal A, Bähr M, Breuer K, Chen MM, Llamazares-Prada M, Hartmann M, Schönung M, Correia N, Trumpp A, Abdullah Y, Klingmüller U, Mughal SS, Brors B, Westermann F, Ulrich E, Autry RJ, Schlesner M, Vosberg S, Herold T, Greif PA, Pfeifer D, Lübbert M, Fischer T, Heidel FH, Gebhard G, Walter W, Haferlach T, Eisfeld AK, Mrózek K, Nicolet D, Bullinger L, Smeenk L, Erpelinck-Verschueren C, Mulet-Lazaro R, Delwel R, Ernst A, Scherer M, Lutsik P, Jeremias I, Döhner K, Döhner H, Lipka DB, Plass C.
Blood Cancer Discov. 2025 Mar 31. doi: 10.1158/2643-3230.BCD-24-0278. Online ahead of print. PMID: 40162972

36. Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia - long-term follow-up with focus on younger patients. Rautenberg C, Middeke JM, Röllig C, Stelljes M, Gaidzik V, Kriege O, Verbeek M, Koch K, Unglaub JM, Thol F, Krause SW, Hänel M, Neuerburg C, Vucinic V, Jehn CF, Wass M, Heuser M, Fransecky L, Chemnitz J, Holtick U, Schäfer-Eckart K, Schröder J, Kraus S, Krüger W, Kaiser U, Scholl S, Kobbe G, Jäger PS, Alakel N, von Bonin M, Sockel K, Hanoun M, Platzbecker U, Holderried TAW, Morgner A, Sauer T, Götze KS, Wagner-Drouet E, Döhner K, Döhner H, Schliemann C, Schetelig J, Bornhäuser M, Germing U, Flossdorf S, Schroeder T, Stölzel F.
Blood Cancer J. 2025 Apr 8;15(1):60. doi: 10.1038/s41408-025-01274-0. PMID: 40199848 No abstract available.

35. Mitigation of atrial fibrillation-related complications with antithrombotic and cytoreductive therapy in patients with Myeloproliferative Neoplasms: Implications from the GSG-MPN bioregistry. Cho HR, Isfort S, Kricheldorf K, Stegelmann F, Klausmann M, Heidel FH, Griesshammer M, Schulz H, Hochhaus A, Göthert J, Schlag R, Hollburg W, Teichmann L, Sockel K, Wilop S, Gezer D, Kirschner M, Döhner K, Brümmendorf TH, Koschmieder S; German Study Group for Myeloproliferative Neoplasms (GSG‐MPN).
Hemasphere. 2025 Mar 17;9(3):e70090. doi: 10.1002/hem3.70090. eCollection 2025 Mar. PMID: 40098896 Free PMC article. No abstract available.

34. Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia. Goede V, Fischer K, Robrecht S, Giza A, Dyer MJ, Eckart MJ, Müller L, Smolej L, Kutsch N, Fink AM, Stilgenbauer S, Hallek MJ.
Blood Adv. 2025 Mar 18:bloodadvances.2024014875. doi: 10.1182/bloodadvances.2024014875. Online ahead of print. PMID: 40101233 No abstract available.

33. XPO1-dependency of DEK::NUP214 leukemia. Charles Cano F, Kloos A, Hebalkar RY, Plenge T, Geffers R, Kirchhoff H, Kattre N, Görlich K, Büsche G, Shcherbata HR, Scherr M, Döhner K, Gabdoulline R, Heuser M.
Leukemia. 2025 May;39(5):1102-1113. Epub 2025 Mar 27.

32. Evaluation and management of hepatic dysfunction, portal hypertension and portal/splanchnic vein thrombosis in patients with myelofibrosis undergoing allogeneic haematopoietic cell transplantation: A practice based survey on behalf of the Chronic Malignancies Working Party of the EBMT. Battipaglia G, Polverelli N, Tuffnell J, Chiusolo P, Robin M, Gambella M, Broers A, Sala E, Passweg J, Furst S, Friis LS, Dulery R, de Witte M, Srour M, Finazzi MC, Wehr C, Nagler A, Richardson D, Bethge W, Clark A, Drozd-Sokolowska J, Raj K, Czerw T, Hernández-Boluda JC, McLornan DP.
Curr Res Transl Med. 2025 Jan-Mar;73(1):103476. doi: 10.1016/j.retram.2024.103476. Epub 2024 Oct 29. PMID: 39461096

31. Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia. Pullarkat V, Pratz KW, Döhner H, Recher C, Thirman MJ, DiNardo CD, Fenaux P, Schuh AC, Wei AH, Pigneux A, Jang JH, Juliusson G, Miyazaki Y, Selleslag D, Arellano ML, Liu C, Ridgeway JA, Potluri J, Schuler J, Konopleva M.
Blood Cancer J. 2025 Mar 28;15(1):49. doi: 10.1038/s41408-025-01263-3. PMID: 40155601 No abstract available.

30. Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party. Duque-Afonso J, Finke J, Ngoya M, Galimard JE, Schetelig J, Eder M, Rösler W, Bug G, Neubauer A, Edinger M, Wulf GG, Jindra P, Einsele H, Stelljes M, Selleslag D, Wagner-Drouet EM, Bunjes D, Spyridonidis A, Brissot E, Nagler A, Ciceri F, Mohty M.
Bone Marrow Transplant. 2025 Mar;60(3):373-379. doi: 10.1038/s41409-024-02499-6. Epub 2024 Dec 19. PMID: 39702670

29. Subgrouping germinal center-derived B-cell lymphomas based on machine learning-deduced DNA methylation modules. Glaser S, Fischer A, Martínez-Manjón JE, López C, Kretzmer H, Burkhardt B, Hübschmann D, Hummel M, Klapper W, Kolarova J, Kreuz M, Ott G, Radlwimmer B, Rosolowski M, Schlesner M, Rosenwald A, Stilgenbauer S, Wagener R, Zwir I, Trümper L, Küppers R, Lichter P, Ammerpohl O, Del Val C, Siebert R; ICGC MMML-Seq consortium.
Leukemia. 2025 Mar 10. doi: 10.1038/s41375-025-02533-6. Online ahead of print. PMID: 40065077 No abstract available.

28. Outcome of Patients with IDH-mutated AML following Allogeneic Stem Cell Transplantation - a Retrospective Analysis on behalf of the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy, DRST. Schroeder T, Flossdorf S, Schuh C, Pabst C, Stadler M, Schetelig J, Wehr C, Stelljes M, Sala E, Burchert A, Winkler J, Reinhardt HC, Kröger N, Fleischhauer K, Rautenberg C.
Transplant Cell Ther. 2025 May;31(5):303.e1-303.e9. Epub 2025 Mar 7.

27. CXCR4 Inhibition Enhances the Efficacy of CD19 Monoclonal Antibody-Mediated Extermination of B-Cell Lymphoma. Khunti N, Kumar M, Datta M, Harelimana JD, Harms M, Albers D, Kirchhoff F, Münch J, Stenger S, Buske C, Maity PC.
Int J Mol Sci. 2025 Feb 26;26(5):2024.

26. Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial. Hoffmann S, Schrezenmeier E, Desmarets M, Halleck F, Durrbach A, Peters L, Tremmel AT, Seidel A, Führer M, Bachmann F, Schrezenmeier J, Greiner J, Körper S, Hofmann H, Ludwig C, Vieweg C, Jahrsdörfer B, Budde K, Schmidt M, Münch J, Joher N, Daguindau E, Grüner B, Brunotte G, Vauchy C, Seifried E, Bradshaw D, Estcourt LJ, Roberts DJ, Toussirot E, Rijnders B, Tiberghien P, Schrezenmeier H.
EBioMedicine. 2025 Feb 27;113:105613. Epub 2025 Feb 27.

25. The significance of PAX5 in Merkel cell carcinoma. Chteinberg E, Kolarova J, Vogt J, Macamo A, Bormann F, Kretzmer H, Speel EJ, van den Oord J, Schneider C, Stilgenbauer S, Becker JC, Winnepenninckx V, Biessen E, Zenke M, Kurz AK, Siebert R, Zur Hausen A.
J Pathol. 2025 May;266(1):81-94. Epub 2025 Mar 4.

24. Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment - an intraindividual analysis by the German Study Group for MPN (GSG-MPN). Manz K, Heidel FH, Koschmieder S, Schlag R, Lipke J, Stegelmann F, Griesshammer M, Klausmann M, Crodel C, Hochhaus A, Schulz H, Göthert JR, Al-Ali H, Becker H, Reiter A, Beutel G, Kricheldorf K, Brümmendorf TH, Hoffmann W, Döhner K, Isfort S; German Study Group for Myeloproliferative Neoplasms (GSG-MPN).
Leukemia. 2025 Apr;39(4):864-875. Epub 2025 Feb 25.

23. Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia. Heyman BM, Opat SS, Wahlin BE, Dimopoulos MC, Castillo JJ, Tedeschi A, Tam CS, Buske C, Owen RG, Leblond V, Trotman J, Barnes G, Chan WY, Schneider J, Allewelt H, Cohen A, Matous JV.
Blood Adv. 2025 Feb 25;9(4):722-728. doi: 10.1182/bloodadvances.2024014115. PMID: 39626287 Clinical Trial.

22. Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia. Tan YH, Yoon DH, Davies AJ, Buske C, Boo YL, Somasundaram N, Lim F, Ong SY, Jeyasekharan A, Izutsu K, Kim WS, Chan JY.
Discov Oncol. 2025 Feb 14;16(1):181. doi: 10.1007/s12672-025-01860-5. PMID: 39951161 Review.

21. Future perspectives of fertility protection. Bundschu K, Aleksandrova-Yankulovska S, Denzer C, Dornbrach T, Eberhart S, Glisic L, Barata AG, Gündel H, Hönig K, Janni W, Khinda K, Rafensteiner L, Siebert R, Steger F, Stilgenbauer S, Wabitsch M, Wiesmüller L, Wilhelm M, Wojak B, Hancke K.
J Reprod Immunol. 2025 Feb 12;168:104455. doi: 10.1016/j.jri.2025.104455. Epub 2025 Feb 12.

20. Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL. Arseni L, Sigismondo G, Yazdanparast H, Hermansen JU, Mack N, Ohl S, Kalter V, Iskar M, Kalxdorf M, Friedel D, Rettel M, Paul Y, Ringshausen I, Eldering E, Dubois J, Kater AP, Zapatka M, Roessner PM, Tausch E, Stilgenbauer S, Dietrich S, Savitski MM, Skånland SS, Krijgsveld J, Lichter P, Seiffert M.
Nat Commun. 2025 Jan 26;16(1):1041.

19. MRD-guided zanubrutinib, venetoclax and obinutuzumab in relapsed CLL: primary endpoint analysis from the CLL2-BZAG trial. Fürstenau M, Robrecht S, Schneider C, Tausch E, Giza A, Ritgen M, Bittenbring JT, Hebart H, Schöttker B, Illert ALL, Graeven U, Stoltefuss A, Heinrich B, Eckert R, Fink AM, Stumpf J, Fischer K, Al-Sawaf O, Simon F, Kleinert F, Weiss J, Kreuzer KA, Schilhabel A, Brüggemann M, Langerbeins P, Stilgenbauer S, Eichhorst B, Hallek MJ, Cramer P. 
Blood. 2025 Mar 20;145(12):1282-1292.

18. Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia. Lang F, Voss A, Kobbe G, Junghanss C, Beck J, Viardot A, Wendelin K, Panse J, Heberling L, Vucinic V, Böll B, Topp M, Hoelzer D, Serve H, Goekbuget N, Ottmann OG, Pfeifer H.
Leuk Lymphoma. 2025 Feb 8:1-9. doi: 10.1080/10428194.2025.2460737. Online ahead of print. PMID: 39921529

17. Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL. Pavlova S, Malcikova J, Radova L, Bonfiglio S, Cowland JB, Brieghel C, Andersen MK, Karypidou M, Biderman B, Doubek M, Lazarian G, Rapado I, Vynck M, Porret NA, Andres M, Rosenberg D, Sahar D, Martínez-Laperche C, Buño I, Hindley A, Donaldson D, Sánchez JB, García-Marco JA, Serrano-Alcalá A, Ferrer-Lores B, Fernández-Rodriguez C, Bellosillo B, Stilgenbauer S, Tausch E, Nikdin H, Quinn F, Atkinson E, van de Corput L, Yildiz C, Bilbao-Sieyro C, Florido Y, Thiede C, Schuster C, Stoj A, Czekalska S, Chatzidimitriou A, Laidou S, Bidet A, Dussiau C, Nollet F, Piras G, Monne M, Smirnova S, Nikitin E, Sloma I, Claudel A, Largeaud L, Ysebaert L, Valk PJM, Christian A, Walewska R, Oscier D, Sebastião M, da Silva MG, Galieni P, Angelini M, Rossi D, Spina V, Matos S, Martins V, Stokłosa T, Pepek M, Baliakas P, Andreu R, Luna I, Kahre T, Murumets Ü, Pikousova T, Kurucova T, Laird S, Ward D, Alcoceba M, Balanzategui A, Scarfo L, Gandini F, Zapparoli E, Blanco A, Abrisqueta P, Rodríguez-Vicente AE, Benito R, Bravetti C, Davi F, Gameiro P, Martinez-Lopez J, Tazón-Vega B, Baran-Marszak F, Davis Z, Catherwood M, Sudarikov A, Rosenquist R, Niemann CU, Stamatopoulos K, Ghia P, Pospisilova S.
Hemasphere. 2025 Jan 20;9(1):e70065. doi: 10.1002/hem3.70065. eCollection 2025 Jan.

16. Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome- paving the path towards precision medicine: a case report. Seeling C, Dahlum S, Marienfeld R, Jan V, Rack B, Gerstenmaier U, Beer AJ, Mayer-Steinacker R, Thaiss W, Barth TFE, Seufferlein T, Gaisa NT, Stilgenbauer S, Janni W, Siebert R, Döhner H, Gaidzik VI.
J Cancer Res Clin Oncol. 2025 Jan 16;151(1):37.

15. Disease characteristics and outcomes of acute myeloid leukemia in germline RUNX1 deficiency (Familial Platelet Disorder with associated Myeloid Malignancy). Ernst MPT, Versluis J, Valk PJM, Bierings M, Tamminga RYJ, Hooimeijer LH, Döhner K, Gresele P, Tawana K, Langemeijer SMC, Van der Reijden BA, Podgornik H, Sever M, Tvedt THA, Vulliamy T, Fitzgibbon J, Dokal I, Baliakas P, Bastida JM, Pohlkamp C, Haferlach T, Larcher L, Soulier J, Schutgens REG, Freson K, Duployez N, Löwenberg B, Ericson K, Cammenga J, Ripperger T, Raaijmakers MHGP.
Hemasphere. 2025 Jan 16;9(1):e70057. doi: 10.1002/hem3.70057. eCollection 2025 Jan.

14. Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with NPM1-mutated AML. Cocciardi S, Saadati M, Weiß N, Späth D, Kapp-Schwoerer S, Schneider I, Meid A, Gaidzik VI, Skambraks S, Fiedler W, Kühn MWM, Germing U, Mayer KT, Lübbert M, Papaemmanuil E, Thol F, Heuser M, Ganser A, Bullinger L, Benner A, Döhner H, Döhner K.
Hemasphere. 2025 Jan 15;9(1):e70060. doi: 10.1002/hem3.70060. eCollection 2025 Jan. PMID: 39816531 Free PMC article.

13. Correction: Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic. Arndt V, Doege D, Fröhling S, Albers P, Algül H, Bargou R, Bokemeyer C, Bornhäuser M, Brandts CH, Brossart P, Brucker SY, Brümmendorf TH, Döhner H, Gattermann N, Hallek M, Heinemann V, Keilholz U, Kindler T, von Levetzow C, Lordick F, Neumann UP, Peters C, Schadendorf D, Stilgenbauer S, Zander T, Zips D, Braun D, Seufferlein T, Nettekoven G, Baumann M.
J Cancer Res Clin Oncol. 2025 Jan 18;151(1):39.

12. Acute Effects of Slow-Paced Breathing on Measures of HRV in Hospitalized Patients With Bilateral COVID-19 Pneumonia: A Secondary Analysis of a Randomized Clinical Trial. Balint EM, Grüner B, Gündel H, Haase S, Kaw-Geppert M, Thayer J, Weimer K, Jarczok MN.
Psychosom Med. 2025 Jan 1;87(1):74-83.

11. The sarcoma ring trial: a case-based analysis of inter-center agreement across 21 German-speaking sarcoma centers. Roohani S, Handtke J, Hummedah K, Albertsmeier M, Andreou D, Apostolidis L, Augustin M, Bauer S, Billner M, Bösch F, Deinzer CKW, Deventer N, Duprée A, Eckert F, Engel L, Fechner K, Fritzsche H, Gaidzik V, Ghani S, Grützmann R, Guder WK, Hamacher R, Hecker JS, Hendricks A, Hillmann A, Houben P, Hübner G, Ivanyi P, Jentsch C, Jordan M, Kappl P, Kaths M, Kessler T, Kirchberg J, Knebel C, Krempien R, Lehner B, Lenze U, Lindner LH, Lörsch AM, Maguire N, Müller S, Piso P, Potkrajcic V, Reichardt P, Richter S, Schewe S, Schiffmann LM, Scholten F, Striefler JK, Schwarzbach M, Seidensaal K, Semrau S, Szkandera J, Szuszies CJ, Timmermann B, Tuscherer A, Wiegering A, Winkelmann MT, Kaul D, Jakob J.
J Cancer Res Clin Oncol. 2025 Jan 4;151(1):30.

10. Radioimmunotherapy of acute myeloid leukemia: a critical assessment of its prospects and limitations. Bunjes D.
Expert Rev Hematol. 2025 Jan;18(1):81-89. Epub 2025 Jan 10.

9. Endpoint Surrogacy in First-Line Chronic Lymphocytic Leukemia. Simon F, Ligtvoet R, Robrecht S, Cramer P, Kutsch N, Fürstenau M, Goede V, von Tresckow J, Langerbeins P, Fink AM, Huber H, Tausch E, Schneider C, Wendtner CM, Ritgen M, Dreyling M, Müller L, Jacobasch L, Heinz WJ, Vehling-Kaiser U, Sivcheva L, Böttcher S, Dreger P, Illmer T, Gregor M, Staber PB, Stilgenbauer S, Niemann CU, Kater AP, Fischer K, Eichhorst B, Hallek M, Al-Sawaf O.
J Clin Oncol. 22025 Feb;43(4):381-391. Epub 2024 Aug 23.

8. Peripheral Neuropathy in the Phase 3 ASPEN Study of Bruton Tyrosine Kinase Inhibitors for Waldenström Macroglobulinemia. Heyman BM, Opat SS, Wahlin BE, Dimopoulos MAA, Castillo JJ, Tedeschi A, Tam CS, Buske C, Owen RG, Leblond V, Trotman J, Barnes G, Chan WY, Schneider J, Allewelt H, Cohen AC, Matous JV.
Blood Adv. 2025 Feb 25;9(4):722-728.

7. Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial. Langerbeins P, Robrecht S, Nieper P, Cramer P, Fürstenau M, Al-Sawaf O, Simon F, Fink AM, Kreuzer KA, Vehling-Kaiser U, Tausch E, Schneider C, Müller L, Eckart MJ, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M, Zahn MO, Dörfel S, Staib P, Behlendorf T, Hensel M, Hebart H, Klaproth H, Block A, Liersch R, Hauch U, Heinrich B, Wendtner CM, Fischer K, Stilgenbauer S, Eichhorst B, Hallek M. 
J Clin Oncol. 2025 Feb;43(4):392-402. Epub 2024 Nov 27.

6. Intestinal perforation following allogeneic stem cell transplantation caused by Epstein-Barr virus-positive mucocutaneous ulcer. Hirschbühl K, Schaller T, Märkl B, Amerein A, Gebhard M, Braun G, Wasserberg S, Sala E, Trepel M, Schmid C.
Haematologica. 2025 Apr 1;110(4):1038-1040. Epub 2024 Dec 5.

5. Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma. Grieb N, Oeser A, Ferle M, Hanke F, Flossdorf S, Sauer S, Goldschmidt H, Müller-Tidow C, Salwender HJ, Fenk R, Engelhardt M, Zeiser R, Vucinic V, Franke GN, Blau IW, Teschner D, Einsele H, Kimmich C, Kull M, Besemer B, Gagelmann N, Kröger N, Neumuth T, Platzbecker U, Merz M; German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST).
Bone Marrow Transplant. 2025 Mar;60(3):335-345. Epub 2024 Dec 5.

4. Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study. Shumilov E, Wurm-Kuczera R, Kerkhoff A, Wang M, Melchardt T, Holtick U, Bacher U, Staber PB, Mazzeo P, Leng C, Böckle D, Hölscher AS, Kauer J, Rotter N, Vucinic V, Rudzki JD, Nachbaur D, Bücklein VL, Schnetzke U, Krämer I, Wille K, Hasse A, von Tresckow B, Hänel M, Koenecke C, Velazquez GF, Viardot A, Schmid C, Thurner L, Wolf D, Subklewe M, Dreyling M, Dreger P, Dietrich S, Keller U, Jaeger U, Greil R, Pabst T, Lenz G, Chapuy B.
Blood Adv. 2024 Dec 11:bloodadvances.2024014903. doi: 10.1182/bloodadvances.2024014903. Online ahead of print. PMID: 39661985

3. Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project. Voso MT, Guarnera L, Lehmann S, Döhner K, Döhner H, Platzbecker U, Russell NH, Dillon RJ, Thomas I, Ossenkoppele GJ, Haferlach T, Vignetti M, La Sala E, Piciocchi A, Fazi P, Villaverde Ramiro Á, Tur Giménez L, Gurnari C, Bullinger L, Hernandez JM.
Blood. 2025 Jan 9;145(2):234-243.

2. Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance. Sobas MA, Turki AT, Ramiro AV, Sánchez AH, Elicegui JM, González T, Melchor RA, Abáigar M, Tur L, Dall'Olio D, Sträng E, Tettero JM, Castellani G, Benner A, Döhner K, Thiede C, Metzeler KH, Haferlach T, Damm F, Ayala R, Martínez-López J, Mills KI, Sierra J, Lehmann S, Porta MGD, Mayer J, Reinhardt D, Medina RV, Schulze-Rath R, Barbus M, Hernández-Rivas JM, Huntly BJP, Ossenkoppele G, Döhner H, Bullinger L.
Haematologica. 2025 May 1;110(5):1126-1140. Epub 2024 Nov 7.

1. Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine. Bresser H, Schmoor C, Grishina O, Pfeifer D, Thomas J, Rehman UU, Crysandt M, Jost E, Thol F, Heuser M, Götze KS, Schlenk RF, Salih HR, Schittenhelm MM, Heil G, Schwaenen C, Müller-Tidow C, Brugger W, Kündgen A, de Wit M, Giagounidis A, Scholl S, Neubauer A, Krauter J, Bug G, May AM, Wäsch R, Duyster J, Döhner K, Ganser A, Döhner H, Hackanson B, Becker H, Lübbert M.
Eur J Haematol. 2025 Feb;114(2):231-237. Epub 2024 Oct 13.